Key Takeaways
- GeoVax’s GEO-MVA vaccine aims to address the global orthopoxvirus vaccine shortage.
- The company plans to start a pivotal Phase 3 clinical trial in the second half of 2026.
- GeoVax received regulatory support from the European Medicines Agency (EMA) to expedite development.
Vaccine Development Update
GeoVax Labs, Inc., a clinical-stage biotechnology company, has announced significant progress on its vaccine candidate, GEO-MVA. This Modified Vaccinia Ankara (MVA)-based vaccine targets mpox and smallpox and aims to mitigate the global shortage of orthopoxvirus vaccines. The company plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026 under an expedited regulatory pathway.
GEO-MVA is positioned to tackle recurrent mpox outbreaks and adapt to emerging viral strains, as well as address the depletion of government stockpiles following recent outbreaks. GeoVax is actively engaging with public health authorities and regulatory agencies to align GEO-MVA with biosecurity procurement frameworks.
In 2025, GeoVax achieved several milestones, including receiving formal Scientific Advice from the European Medicines Agency (EMA) to streamline development, completing the large-scale manufacturing of clinical-grade GEO-MVA, and preparing for the pivotal trial. However, the company faced challenges as BARDA terminated its contract for convenience in April 2025.
In remarks on the company’s advancements, David Dodd, Chairman and CEO of GeoVax, highlighted the importance of GEO-MVA in addressing the global supply constraints of orthopoxvirus vaccines. He emphasized the vaccine’s role in enhancing public health preparedness and biosecurity.
As GeoVax moves forward, the upcoming Phase 3 clinical trial is a vital step toward achieving commercial readiness for GEO-MVA. The company remains focused on developing a diversified and domestic vaccine supply strategy that addresses both current health crises and future outbreaks.
The ongoing engagement with international regulatory stakeholders further demonstrates GeoVax’s commitment to ensuring that its vaccine meets the necessary public health standards and addresses the urgent needs arising from the global health landscape.
The content above is a summary. For more details, see the source article.